Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Dec;38(6):557–566. doi: 10.1111/j.1365-2125.1994.tb04397.x

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.

J C Bloomer 1, S J Baldwin 1, G J Smith 1, A D Ayrton 1, S E Clarke 1, R J Chenery 1
PMCID: PMC1364919  PMID: 7888294

Abstract

1. The metabolism of granisetron was investigated in human liver microsomes to identify the specific forms of cytochrome P450 responsible. 2. 7-hydroxy and 9'-desmethyl granisetron were identified as the major products of metabolism following incubation of granisetron with human liver microsomes. At low, clinically relevant, concentrations of granisetron the 7-hydroxy metabolite predominated. Rates of granisetron 7-hydroxylation varied over 100-fold in the human livers investigated. 3. Enzyme kinetics demonstrated the involvement of at least two enzymes contributing to the 7-hydroxylation of granisetron, one of which was a high affinity component with a Km of 4 microM. A single, low affinity, enzyme was responsible for the 9'-desmethylation of granisetron. 4. Granisetron caused no inhibition of any of the cytochrome P450 activities investigated (CYP1A2, CYP2A6, CYP2B6, CYP2C9/8, CYP2C19, CYP2D6, CYP2E1 and CYP3A), at concentrations up to 250 microM. 5. Studies using chemical inhibitors selective for individual P450 enzymes indicated the involvement of cytochrome P450 3A (CYP3A), both pathways of granisetron metabolism being very sensitive to ketoconazole inhibition. Correlation data were consistent with the role of CYP3A3/4 in granisetron 9'-desmethylation but indicated that a different enzyme was involved in the 7-hydroxylation.

Full text

PDF
557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aapro M. S. 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs. 1991 Oct;42(4):551–568. doi: 10.2165/00003495-199142040-00002. [DOI] [PubMed] [Google Scholar]
  2. Allen A., Asgill C. C., Pierce D. M., Upward J., Zussman B. D. Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects. Eur J Clin Pharmacol. 1994;46(2):159–162. doi: 10.1007/BF00199881. [DOI] [PubMed] [Google Scholar]
  3. Aoyama T., Yamano S., Waxman D. J., Lapenson D. P., Meyer U. A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H. V. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989 Jun 25;264(18):10388–10395. [PubMed] [Google Scholar]
  4. Berthou F., Flinois J. P., Ratanasavanh D., Beaune P., Riche C., Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos. 1991 May-Jun;19(3):561–567. [PubMed] [Google Scholar]
  5. Burke M. D., Thompson S., Elcombe C. R., Halpert J., Haaparanta T., Mayer R. T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol. 1985 Sep 15;34(18):3337–3345. doi: 10.1016/0006-2952(85)90355-7. [DOI] [PubMed] [Google Scholar]
  6. Campbell M. E., Grant D. M., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos. 1987 Mar-Apr;15(2):237–249. [PubMed] [Google Scholar]
  7. Cassidy J., Raina V., Lewis C., Adams L., Soukop M., Rapeport W. G., Zussman B. D., Rankin E. M., Kaye S. B. Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. Br J Cancer. 1988 Nov;58(5):651–653. doi: 10.1038/bjc.1988.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Combalbert J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J. P., Maurel P. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos. 1989 Mar-Apr;17(2):197–207. [PubMed] [Google Scholar]
  9. DeLuca J. G., Dysart G. R., Rasnick D., Bradley M. O. A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog. Biochem Pharmacol. 1988 May 1;37(9):1731–1739. doi: 10.1016/0006-2952(88)90436-4. [DOI] [PubMed] [Google Scholar]
  10. Dirven H. A., Peters J. G., Gibson G. G., Peters W. H., Jongeneelen F. J. Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes. Biochem Pharmacol. 1991 Oct 9;42(9):1841–1844. doi: 10.1016/0006-2952(91)90524-9. [DOI] [PubMed] [Google Scholar]
  11. Fischer V., Baldeck J. P., Tse F. L. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos. 1992 Jul-Aug;20(4):603–607. [PubMed] [Google Scholar]
  12. Fischer V., Vickers A. E., Heitz F., Mahadevan S., Baldeck J. P., Minery P., Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994 Mar-Apr;22(2):269–274. [PubMed] [Google Scholar]
  13. Funae Y., Imaoka S. Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats. Biochim Biophys Acta. 1987 Dec 7;926(3):349–358. doi: 10.1016/0304-4165(87)90221-2. [DOI] [PubMed] [Google Scholar]
  14. Gonzalez F. J., Schmid B. J., Umeno M., Mcbride O. W., Hardwick J. P., Meyer U. A., Gelboin H. V., Idle J. R. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA. 1988 Mar;7(2):79–86. doi: 10.1089/dna.1988.7.79. [DOI] [PubMed] [Google Scholar]
  15. Guengerich F. P., Müller-Enoch D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986 Sep;30(3):287–295. [PubMed] [Google Scholar]
  16. Maurice M., Emiliani S., Dalet-Beluche I., Derancourt J., Lange R. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem. 1991 Sep 1;200(2):511–517. doi: 10.1111/j.1432-1033.1991.tb16212.x. [DOI] [PubMed] [Google Scholar]
  17. Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 1992 Jan 6;6(2):752–758. doi: 10.1096/fasebj.6.2.1371482. [DOI] [PubMed] [Google Scholar]
  18. Meier U. T., Kronbach T., Meyer U. A. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem. 1985 Dec;151(2):286–291. doi: 10.1016/0003-2697(85)90177-0. [DOI] [PubMed] [Google Scholar]
  19. Miners J. O., Smith K. J., Robson R. A., McManus M. E., Veronese M. E., Birkett D. J. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol. 1988 Mar 15;37(6):1137–1144. doi: 10.1016/0006-2952(88)90522-9. [DOI] [PubMed] [Google Scholar]
  20. Otton S. V., Crewe H. K., Lennard M. S., Tucker G. T., Woods H. F. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988 Oct;247(1):242–247. [PubMed] [Google Scholar]
  21. Peter R., Böcker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol. 1990 Nov-Dec;3(6):566–573. doi: 10.1021/tx00018a012. [DOI] [PubMed] [Google Scholar]
  22. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., Maurel P. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):595–606. [PubMed] [Google Scholar]
  23. Schuetz E. G., Schuetz J. D., Grogan W. M., Naray-Fejes-Toth A., Fejes-Toth G., Raucy J., Guzelian P., Gionela K., Watlington C. O. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys. 1992 Apr;294(1):206–214. doi: 10.1016/0003-9861(92)90159-t. [DOI] [PubMed] [Google Scholar]
  24. Schuetz J. D., Beach D. L., Guzelian P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics. 1994 Feb;4(1):11–20. doi: 10.1097/00008571-199402000-00002. [DOI] [PubMed] [Google Scholar]
  25. Sesardic D., Boobis A. R., Murray B. P., Murray S., Segura J., de la Torre R., Davies D. S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990 Jun;29(6):651–663. doi: 10.1111/j.1365-2125.1990.tb03686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  27. Speirs C. J., Murray S., Boobis A. R., Seddon C. E., Davies D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 1986 Dec;22(6):739–743. doi: 10.1111/j.1365-2125.1986.tb02969.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Veronese M. E., Doecke C. J., Mackenzie P. I., McManus M. E., Miners J. O., Rees D. L., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J. 1993 Jan 15;289(Pt 2):533–538. doi: 10.1042/bj2890533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Veronese M. E., Doecke C. J., Mackenzie P. I., McManus M. E., Miners J. O., Rees D. L., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J. 1993 Jan 15;289(Pt 2):533–538. doi: 10.1042/bj2890533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160–166. doi: 10.1016/0003-9861(91)90602-f. [DOI] [PubMed] [Google Scholar]
  31. Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160–166. doi: 10.1016/0003-9861(91)90602-f. [DOI] [PubMed] [Google Scholar]
  32. Wrighton S. A., Brian W. R., Sari M. A., Iwasaki M., Guengerich F. P., Raucy J. L., Molowa D. T., Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990 Aug;38(2):207–213. [PubMed] [Google Scholar]
  33. Wrighton S. A., Stevens J. C., Becker G. W., VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys. 1993 Oct;306(1):240–245. doi: 10.1006/abbi.1993.1506. [DOI] [PubMed] [Google Scholar]
  34. Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990 Feb 6;29(5):1322–1329. doi: 10.1021/bi00457a031. [DOI] [PubMed] [Google Scholar]
  35. Zanger U. M., Vilbois F., Hardwick J. P., Meyer U. A. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry. 1988 Jul 26;27(15):5447–5454. doi: 10.1021/bi00415a010. [DOI] [PubMed] [Google Scholar]
  36. de Bruijn K. M. Tropisetron. A review of the clinical experience. Drugs. 1992;43 (Suppl 3):11–22. doi: 10.2165/00003495-199200433-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES